Finally, patients with EGFR-expressing CRC, who had been previously treated with fluoropyrimidine, irinotecan and oxaliplatin, had a median overall survival of 6.1 months if treated with cetuximab, and 4.6 months if receiving supportive care alone (Jonker et al., 2007). Here, EGFR is linked to colorectal carcinoma.